chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She noticed some shortness of breath upon exertion, especially after her walk; I am not sleeping well, but I  don't sleep well anyway and don't think it's related to the vaccine.; This is a spontaneous report from a contactable consumer (patient). A 83-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration, administered in arm right on 28Feb2021 at 13:20 (at the age of 82-years-old) (Batch/Lot Number: GN6202) as DOSE 1, SINGLE for covid-19 immunization. Vaccination facility type was Physician Office. Vaccine was not administered at Facility. The patient's medical history was not reported. Concomitant medications included a lot of unspecified pills. History of all previous immunization with the Pfizer vaccine considered as suspect was none. Patient had no other vaccines on the same day as the suspect product. Prior Vaccinations (within 4 weeks) was none. Patient stated after her first vaccine dose, over last 5 days on an unspecified date in Mar2021, she noticed some shortness of breath upon exertion, especially after her walk, she wanted to know if it was normal because it only occurred during exertion. Patient also stated that other than that I haven't had any side effects, I am not sleeping well, but I don't sleep well anyway and don't think it's related to the vaccine, she also stated her second dose was scheduled on the 24th day instead of 21st day. Patient stated that she was prescribed an inhaler by her doctor a couple years ago, but she never used it before, but she tried using it yesterday but she did not know if it helped or not, since she only felt the shortness of breath when she was doing a brisk walk. The patient would call doctor will call she would probably just tell me to take my inhaler.Caller states that she noticed that when she takes her 30 minute, daily walks, she is getting some shortness of breath. Caller states that she got her Pfizer COVID vaccine shot, a week and a half ago, and she is wondering if that could be a side effect of the product, or if it is a symptom of COVID. The events did not result in emergency room/ physician office visit. The patient was not admitted to hospital due to events. Relevant test reported as none. Therapeutic measures were taken as a result of she noticed some shortness of breath upon exertion, especially after her walk (dyspnoea exertional). The outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
PFIZER VIAL SHOULD HAVE BEEN RECONSTITUTED WITH 1.8 ML NOMAL SALINE AND WAS ONLY RECONSTITUTED WITH 0.8ML NS. PATIENT RECEIVED ULTRA CONCENTRATED VACCINE DOSE.  PATIENT WAS UNABLE TO BE REACHED TO DISCUSS POTENTIAL ADVERSE REACTIONS. NO PCP LISTED FOR PATIENT.
Initial reaction was noted on 4/22 she felt tired.  4/22 high heart rate (95) and BP was elevated (150/70 which is high for her). 4/24 in evening, woke up with an uncomfortable feeling. Felt some chest pain. Then she felt better for a day on 4/24. Then tired again 4/25. 4/28  she developed redness in her face. She feels nausea. She feels drowsy. Has heaviness in the chest when lying down. She has trouble breathing, when she has to walk up the hill.. Body aches worse after vaccine.  She cannot sleep well. She spoke to an allergist 4/23, who advised her to go to ED, she did not go. Husband called on call MD, who advised her to go to ED 4/23, she did not go. 4/28 called Covid 19 hotline, advised to go to ED.
Very sore arm, muscle aches, fatigue, slight off and on headache, dry eyes, slight nausea, tickle in throat with light coughing.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Visual Changes/Disturbances-Mild, Additional Details: PT fainted and lost conciousness couple minutes after administration of vaccine. Thankfully PT was held onto the chair by another patient and he did not fall out of his seat. After regaining conciousness after a couple second, pt rested on the floor until he felt well enough to leave.
Site: Pain at Injection Site-Mild, Systemic: Fainting / Unresponsive-Medium, Additional Details: PATIENT STOOD UP AND THEN SAID SHE FELT FAINT.  THE IMMUNIZER TOLD HER TO SIT DOWN ON THE CHAIR AND BEFORE SHE COULD TO THIS SHE FAINTED.
Fever 100.0, redness & swelling at site location on left arm. 8/6/2015 redness & swelling radiating to left elbow.
Discharge Provider:  Primary Care Provider at Discharge: medical doctor Admission Date: 7/25/2022 Discharge Date: 7/27/2022  PRESENTING PROBLEM: Hypoxemia Pneumonia due to COVID-19 virus COVID-19   HOSPITAL COURSE:   Patient is a 68 y.o. female with a PMH chronic obstructive pulmonary disease, hypertension, and anxiety who presents to hospital on 7/25/2022 with cough and SOB.  The patient lives with her daughter who was recently diagnosed with COVID-19.  The patient developed symptoms on 07/24/2022.   Upon presentation to the emergency department she was noted to be satting 86% air and was placed on 2 L nasal cannula with improvement.  Chest x-ray was completed and negative for infiltrate.  While hospitalized the patient received remdesivir 3 days.  Also received Decadron for total of 3 days will transition to low-dose oral prednisone for 5 additional days to also treat the chronic obstructive pulmonary disease exacerbation.  The patient notes that she does have some mild jittering from the steroids.  At baseline the patient is not on a home inhaler for maintenance.  A prescription for 1 month Advair inhaler was given as well as an inhaler for albuterol.  Patient was instructed to take Mucinex for the next week to help facilitate mucus secretion.   While hospitalized the patient's home lisinopril was stopped due to complaint of dry cough.  Will switch over to Arb as there is less incidence of a dry cough.  Started losartan 50 mg daily during the hospital stay which she has tolerated.  Recommend outpatient follow-up with PCP in 1 week.  Due to hypokalemia while hospitalized would recommend follow-up BMP in 1 week.  The patient's potassium was optimized with oral replacement prior to discharge.
Initial unsolicited report received from a consumer on 29 October 2015. This case involves a (age unknown) female patient who was vaccinated with a [route and dose series not reported] dose of FLU VACCINE (batch number, expiry date and site of administration were not reported) on an unspecified date. Pre-existing physician diagnosed allergies, birth defects, medical conditions was reported as diabetes and celiac disease. It was reported that, patient had received several flu vaccines over the past years. Concomitant medications were not reported. On an unspecified date, "1 to 2 weeks" following the vaccination patient experienced erratic blood sugars. Lab data and corrective treatment were not reported. The outcome of event was recovered. Follow up information received from physician on 30 November 2015. This case involves 09-years-old patient who was vaccinated with 0.5 ml dose of Flu vaccine (batch number: UI496AB, expiry date: 30-Jun-2016) in left deltoid on 29 October 2015. The batch number provided corresponds to the product INFLUENZA QUADRIVAL A-B VACCINE. Concomitant medications included HUMALOG insulin pump. List of documents held by sender: none.
Head ache, Body Ache, Chills, Low grade fever, swollen on injection site, upset stomach
lip and facial numbness x 6 hours lip tingling and decreased sensation x 48 hours
32 weeks pregnant, still pregnant. Side effect is dizziness two days after the first COVID vaccine
patient reported hives on her chest that started several days after receiving the vaccine. It persisted for about a month, but she had not tried Benadryl or more consistent use of a topical steroid.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a adult patient who received SHINGRIX for prophylaxis. On 21st November 2018, the patient received SHINGRIX. In November 2018, less than a week after receiving SHINGRIX, the patient experienced injection site pain and injection site erythema. On an unknown date, the outcome of the injection site pain and injection site erythema were unknown. It was unknown if the reporter considered the injection site pain and injection site erythema to be related to SHINGRIX. Additional information was reported as follows: The age at vaccination was not reported. The age group was not reported, but was captured as adult as per the vaccine indication.  The patient was vaccinated with SHINGRIX on Wednesday. The patient stated that the pain had increased each day due to the shot.
pain when moving right arm up and down or to the side; Right arm throbbing , started to give pain; fever; chills; a little" tiredness "; pain is in upside of elbow and now its going towards shoulder; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (pain when moving right arm up and down or to the side), PAIN (Right arm throbbing , started to give pain), PYREXIA (fever), CHILLS (chills) and FATIGUE (a little" tiredness ") in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 028A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for an unreported indication: CORTISONE (at right shoulder.) on 15-Feb-2021. Concurrent medical conditions included Drug allergy (Allergies to Augmentin.). Concomitant products included OMEPRAZOLE for Acid reflux (esophageal), ANASTROZOLE (ANASTRAZOLE DENK) for Cancer, SIMVASTATIN for Cholesterol, LOSARTAN for Hypertension, LEVOTHYROXINE for Thyroid disorder.   On 03-Mar-2021 at 4:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Mar-2021, the patient experienced PAIN IN EXTREMITY (pain when moving right arm up and down or to the side), PAIN (Right arm throbbing , started to give pain), PYREXIA (fever), CHILLS (chills), FATIGUE (a little" tiredness ") and ARTHRALGIA (pain is in upside of elbow and now its going towards shoulder). The patient was treated with PARACETAMOL (TYLENOL) for Pain, at an unspecified dose and frequency. On 06-Mar-2021, PYREXIA (fever), CHILLS (chills) and FATIGUE (a little" tiredness ") had resolved. At the time of the report, PAIN IN EXTREMITY (pain when moving right arm up and down or to the side) and ARTHRALGIA (pain is in upside of elbow and now its going towards shoulder) had not resolved and PAIN (Right arm throbbing , started to give pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   On an unknown date blood work up was done and reports were normal.   This case was linked to MOD-2021-090316 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: Events added On 02-Jun-2021: follow-up received on 2 June 2021. reporter details updatedpatient height and weight updated.allergies updated.concomitant medications updated.vaccination facility details updated. On 28-Jul-2021: Followup received on 28 JUL 2021, Patient gave consent to contact HCP, Possible NNI,; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Rash near injection site day 9 after vaccine was administered. Itchy at times. Applued Benadryl cream on 2/9/2021
suspected vaccination failure; shingles; nerve pain/sensitivity; This case was reported by a nurse via sales rep and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix and Shingrix, the patient experienced suspected vaccination failure (serious criteria GSK medically significant), shingles and nerve pain. On an unknown date, the outcome of the suspected vaccination failure, shingles and nerve pain were unknown.   It was unknown if the reporter considered the suspected vaccination failure, shingles and nerve pain to be related to Shingrix and Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received two doses of Shingrix and experienced shingles and nerve pain/sensitivity. Consent to follow up was denied. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting.
Puffiness of the face on the left side for her son; This spontaneous case was reported by an other health care professional and describes the occurrence of SWELLING FACE (Puffiness of the face on the left side) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045B21A) for COVID-19 vaccination.     Concurrent medical conditions included Autism.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, the patient experienced SWELLING FACE (Puffiness of the face on the left side). The patient was treated with BENADRYL for Adverse event, at an unspecified dose and frequency and TYLENOL for Adverse event, at an unspecified dose and frequency. At the time of the report, SWELLING FACE (Puffiness of the face on the left side) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications provided.
85 year old female with acute onset of diffuse body rash this am.  On a.m. of 7 Nov 2007, after her exercises, she noticed the body rash.  Rash is non-pruritic.  No pustules or vesicles.  She denies fevers, chills, malaise, fatigue, shortness of breath, chest pains, GI or GU complaints.  Rash, diffuse, generalized (arms, trunk, back, neck, legs, face).
The patient also missed her 2nd dose in the series; She is taking Acyclovir for HSV2; This spontaneous report has received from a pharmacist over by Agent, concerning to 21-year-old female patient. The patient's medical history, concurrent conditions and concomitant medications were unknown by reporter.  On 25-MAR-2020, the patient was vaccinated with the first hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (dose, frequency, route, anatomical location, lot number and expiration date were not provided) for prophylaxis.  On 07-AUG-2020, the patient experienced herpes simplex II (HSV2) and was treated with acyclovir. Furthermore, on an unknown date, the patient missed the second dose in the series of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9).   The outcome of herpes simplex was reported as resolving. The causal relationship between the adverse event and therapy was not assessed.
Patient was inadvertently given adult trivalent flu 0.5ml dose instead of pediatric 0.25 ml dose.
She says this vaccine has knocked her down; She is weak; has no appetite; headache; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION COMPLICATION (She says this vaccine has knocked her down), ASTHENIA (She is weak), DECREASED APPETITE (has no appetite) and HEADACHE (headache) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012F) for COVID-19 vaccination.     The patient's past medical history included Kidney absent.    On 23-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In October 2021, the patient experienced VACCINATION COMPLICATION (She says this vaccine has knocked her down), ASTHENIA (She is weak), DECREASED APPETITE (has no appetite) and HEADACHE (headache). At the time of the report, VACCINATION COMPLICATION (She says this vaccine has knocked her down), ASTHENIA (She is weak), DECREASED APPETITE (has no appetite) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Her health history includes having only one kidney  Concomitant medication use was unknown  Treatment information was unknown
Shortly after receiving vaccine, pt. got very flush, her face turned very red, she stated she wasn't feeling well and described her symptoms as hot, flush, dizzy, shaking and "tingly" feeling - called 911 immediately and EMS responded. Elevated blood pressure.
on the day after vaccine got infection  in buttocks'. and went to ER and had boil removed. After 2nd vaccine on 5/21 body was covered with bumps like chicken pox. will have surgery on 5/25
Patient developed diffuse lesions that are consistent with varicella 2 weeks after his Varicella #1 vaccine. He has had some fever and also left arm/elbow pain (nothing noted on exam).
Small rash developed near his lip; excessive tiredness; he wasnt able to eat.; This is a spontaneous report from a non-contactable consumer (parent, caregiver).  A 13-year-old male patient (reporter's son) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number unknown) via an unspecified route of administration in May2021 about one week ago at 13 years old at 1st dose, single for COVID-19 immunization. The patient was a special needs child who was non verbal autistic. Concomitant medications were not reported. The patient experienced small rash developed near his lip last Thursday (20May2021) and by the weekend (May2021) he was not able to eat. His mom took him to see hcp and antibiotic cefalexin (CEPHALEXIN) was prescribed which was helping. The patient was having excessive tiredness on May2021 but was unsure if related to covid vaccine. Was it common to have excessive tiredness one week after the covid vaccine? Therapeutic measures were taken as a result of small rash developed near his lip, and he was not able to eat. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Dizziness; Diarrhea; Painful joints; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 04May2021 at 10:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included vasculitis, heart disease, stage three kidney disease and allergy to sulpha drugs. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN) and lisinopril (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 09:00 as a single dose for COVID-19 immunisation. On 05May2021 at 00:00, the patient experienced dizziness, diarrhea and painful joints. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness, diarrhea and painful joints was not resolved at the time of the report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
booster; eosinophilic esophagitis (EOE); This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP) from a sales representative.  A patient (no qualifiers provided) received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose number, unknown (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Manufacturer Unknown), for Covid-19 Immunization. The following information was reported: IMMUNISATION (non-serious), outcome "unknown", described as "booster"; EOSINOPHILIC OESOPHAGITIS (non-serious), outcome "unknown", described as "eosinophilic esophagitis (EOE)". Relevant laboratory tests and procedures are available in the appropriate section.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient developed a red, itchy rash in a circular shape at the injection site (right deltoid).  She described the rash as the size of a softball, hot to the touch.  It was also very sore to the touch.
04/14/2022, I came down with COVID-19 and it felt like I was getting a cold. My legs began to ache, and I woke up with a sniffling that developed during this time. I took a test and it came back positive. I was given Paxlovid and it worked great, and quickly my symptoms went away after just one day of using the prescription. COVID-19 Test after 5 day treatment and it came back negative.
Migraine that lasted 36 hours, 101.7 fever (not sure how long), chills, muscle and joint ache
Patient was given MMR vaccine 3-8-10. Was to return 2 wks for KINRIX and then 1 month for Varicella. When returned on 3-22-10 was given Varicella when it should have been KINRIX, no adverse effect. Other than vaccine being given too early, there was no adverse effect.
Date the vial was initially stored in the refrigerator was 12May2022 and Exp: 02May2022; Administered 9 doses of expired Moderna Covid-19 vaccine on 13May2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered 9 doses of expired Moderna Covid-19 vaccine on 13May2022) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator was 12May2022 and Exp: 02May2022) in a 50-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 045J21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-May-2022, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 13-May-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered 9 doses of expired Moderna Covid-19 vaccine on 13May2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator was 12May2022 and Exp: 02May2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered 9 doses of expired Moderna Covid-19 vaccine on 13May2022) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator was 12May2022 and Exp: 02May2022) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. Reporter asked whether patients needs to be revaccinated. The vial did not undergone any temperature excursions. No treatment medication were provided.
09/04/13 well visit received Dtap (4), HIB (4), Hep A (2), PCV13 (4) 12 hours later hand to toe papula rashy with bilateral leg pain. Did not want to walk.